Undisclosed RD cystic kidney disease
Mannin Research is developing therapeutics for vascular diseases. High intraocular eye pressure (IOP) is one of the main causes of glaucoma. Using their proprietary research platform, Mannin is developing a unique molecule that can be administered via eye drops to reduce IOP. This lead indication is being tested for treatment of primary open-angle glaucoma. In addition, Mannin is researching therapeutics that could treat cystic kidney disease, pediatric glaucoma and inflammation. This will enable Mannin to establish a deep pipeline of novel therapeutics.